Business Context and Reporting Period
This Form 8-K, dated May 24, 2022, reports the completion of Halozyme Therapeutics, Inc.'s (Parent) acquisition of Antares Pharma, Inc. (Company). The transaction involved a tender offer followed by a merger under Section 251(h) of the Delaware General Corporation Law, resulting in Antares becoming a wholly-owned subsidiary of Halozyme.
Key Financial Metrics
- Total Consideration: Approximately $957 million paid for shares in the tender offer and merger (excluding fees and expenses).
- Offer Price: $5.60 per share in cash.
- Shares Tendered: 139,371,158 shares (approximately 81.56% of outstanding shares), meeting the minimum condition for the merger.
- New Debt Facility: A $600 million credit facility established on May 24, 2022, consisting of a $350 million revolving credit facility and a $250 million term loan facility.
- Debt Maturity: November 30, 2026.
- Financial Covenants: Maximum consolidated net leverage ratio of 4.75:1.00 (declining to 4.00:1.00) and minimum consolidated interest coverage ratio of 3.00:1.00.
Material Changes
The primary material change is the consolidation of Antares Pharma into Halozyme Therapeutics. All outstanding Antares stock options, performance stock units (PSUs), and restricted stock units (RSUs) were cancelled and converted into cash payments based on the merger consideration. The Company's existing indebtedness was refinanced using proceeds from the new credit facility and Halozyme's existing cash on hand.
Outlook, Risks, and Contingencies
- Use of Proceeds: Borrowings under the new revolving facility will be used for working capital, general corporate purposes, and potential future acquisitions.
- Covenants and Restrictions: The new credit agreement includes affirmative and negative covenants restricting the ability to create liens, incur additional indebtedness, make investments, or dispose of assets without lender consent.
- Collateral: Substantially all assets of Halozyme and its guarantors (excluding real property and intellectual property) are pledged as collateral.
- Future Filings: Audited financial statements of the acquired business and pro forma financial information will be filed by amendment within 71 calendar days.
Investor Verification Checklist
- Verify the final pro forma financial impact of the $957 million acquisition on Halozyme's balance sheet and liquidity.
- Review the full text of the Credit Agreement (Exhibit 10.1) for specific details on interest rate margins and prepayment terms.
- Monitor the upcoming filing of audited financial statements for Antares Pharma to assess the acquired assets and liabilities.
- Confirm the status of any remaining Antares shares not tendered and the subsequent cash payout process.